Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29862406 | 1.00 | PLA2G4A (1.00) | PLA2G4A | |
| SCHEMBL30409253 | 0.92 | PLA2G4A (1.00) | PLA2G4A | |
| SCHEMBL1684107 | 0.92 | PLA2G4A (1.00) | PLA2G4A | |
| SCHEMBL3927580 | 0.92 | PLA2G4A (1.00) | PLA2G4A | |
| SCHEMBL3920407 | 0.91 | PLA2G4A (1.00) | PLA2G4A | |
| SCHEMBL3931043 | 0.89 | PLA2G4A (0.80) | PLA2G4A | |
| SCHEMBL3931744 | 0.88 | PLA2G4A (0.79) | PLA2G4A | |
| SCHEMBL3933767 | 0.88 | PLA2G4A (0.79) | PLA2G4A | |
| SCHEMBL2803694 | 0.88 | PLA2G4A (0.78) | PLA2G4A | |
| SCHEMBL3922106 | 0.87 | PLA2G4A (0.77) | PLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2490689-A2 | INJECTABLE FORMULATIONS FOR INTRA- ARTICULAR OR PERI-ARTICULAR ADMINISTRATION | Panmira Pharmaceuticals, LLC (US) | 2012-08-29 | — | — | EP | claimed |
| WO-2011049979-A2 | INJECTABLE FORMULATIONS FOR INTRA- ARTICULAR OR PERI-ARTICULAR ADMINISTRATION | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | WO | claimed |
| US-12564575-B2 | Early management, mitigation and prevention of sepsis and sepsis-like syndromes, including neo-natal ARDS due to infection, injury or iatrogenesis | OPHIREX, INC (US) | 2026-03-03 | — | — | US | disclosed |
| US-12383531-B2 | PLA2 inhibitors for treatment of pathological conditions caused by hymenoptera envenomation, such as hemolysis, cerebral edema, and acute kidney injury | OPHIREX, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250120949-A1 | USE OF SPLA2 INHIBITORS TO TREAT ENVENOMATION BY SNAKES AND WASPS | OPHIREX, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-12274691-B2 | Envenomation therapies and related pharmaceutical compositions, systems and kits | OPHIREX, INC (US) | 2025-04-15 | — | — | US | disclosed |
| EP-3448378-B1 | PLA2 AND HMG-COA INHIBITORS FOR TREATMENT OF PATHOLOGICAL CONDITIONS CAUSING HEMOLYSIS, CEREBRAL EDEMA, AND ACUTE KIDNEY INJURY | OPHIREX INC (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20220331291-A1 | EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS | OPHIREX INC (US) | 2022-10-20 | — | — | US | disclosed |
| EP-3220902-A2 | ENVENOMATION THERAPIES AND RELATED PHARMACEUTICAL COMPOSITIONS, SYSTEMS AND KITS | Ophirex, Inc. (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-2490689-A2 | INJECTABLE FORMULATIONS FOR INTRA- ARTICULAR OR PERI-ARTICULAR ADMINISTRATION | Panmira Pharmaceuticals, LLC (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011049979-A2 | INJECTABLE FORMULATIONS FOR INTRA- ARTICULAR OR PERI-ARTICULAR ADMINISTRATION | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20100240718-A1 | NOVEL HETEROARYL-SUBSTITUTED ACETONE DERIVATIVE, SUITABLE FOR INHIBITING PHOSPHOLIPASE A2 | WESTFALISCHE WILHELMS UNIVERSITÄT MÜNSTER (DE) | 2010-09-23 | — | — | US | disclosed |
| US-7608633-B2 | Heteroaryl-substituted acetone derivatives as inhibitors of phospholipase A2 | MERCKLE GMBH (DE) | 2009-10-27 | — | — | US | disclosed |
| US-7608633-B2 | Heteroaryl-substituted acetone derivatives as inhibitors of phospholipase A2 | MERCKLE GMBH (DE) | 2009-10-27 | — | — | US | disclosed |
| CN-100513392-C | Heteroaryl substituted acetone derivatives as phospholipase A2Inhibitor of (2) | MERCKLE GMBH (DE) | 2009-07-15 | — | — | CN | disclosed |
| EP-1590324-B1 | NOVEL HETEROARYL-SUBSTITUTED ACETONE DERIVATIVES AS INHIBITORS OF PHOSPHOLIPASE A sb 2 /sb | MERCKLE GMBH (DE) | 2009-03-11 | — | — | EP | disclosed |
| US-20060142366-A1 | Novel heteroaryl-substituted acetone derivatives as inhibitors of phospholipase a2 | MERCKLE GMBH (DE) | 2006-06-29 | — | — | US | disclosed |
| CN-1761649-A | Novel heteroaryl substituted acetone derivatives as phospholipase A2Inhibitor of (2) | MERCKLE GMBH (DE) | 2006-04-19 | — | — | CN | disclosed |
| EP-1590324-A1 | NOVEL HETEROARYL-SUBSTITUTED ACETONE DERIVATIVES AS INHIBITORS OF PHOSPHOLIPASE A sb 2 /sb | MERCKLE GMBH (DE) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004069797-A1 | NOVEL HETEROARYL-SUBSTITUTED ACETONE DERIVATIVES AS INHIBITORS OF PHOSPHOLIPASE A2 | MERCKLE GMBH (DE) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12274691-B2 | Envenomation therapies and related pharmaceutical compositions, systems and kits | PLA2R1, PLA2G12A, ACHE | PLA2G4A 9/4885 |
| US-20060142366-A1 | Novel heteroaryl-substituted acetone derivatives as inhibitors of phospholipase a2 | PLD2, PLA2G1B, PLA2G4A | PLA2G4A 3/4885 |
| US-12383531-B2 | PLA2 inhibitors for treatment of pathological conditions caused by hymenoptera envenomation, such as hemolysis, cerebral edema, and acute kidney injury | PLA2G4A, PLA2G12A, PLA2G6 | PLA2G4A 1/4885 |
| US-20100240718-A1 | NOVEL HETEROARYL-SUBSTITUTED ACETONE DERIVATIVE, SUITABLE FOR INHIBITING PHOSPHOLIPASE A2 | PLD2, PLA2G1B, PLA2G4A | PLA2G4A 3/4885 |
| US-12564575-B2 | Early management, mitigation and prevention of sepsis and sepsis-like syndromes, including neo-natal ARDS due to infection, injury or iatrogenesis | PLA2G12A, PLA2G3, PLA2G1B | PLA2G4A 17/4885 |
| US-20220331291-A1 | EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS | PLA2G12A, PLA2G3, PLA2G1B | PLA2G4A 14/4885 |
| US-20250120949-A1 | USE OF SPLA2 INHIBITORS TO TREAT ENVENOMATION BY SNAKES AND WASPS | PLA2G12A, PLA2G2D, PLAAT2 | PLA2G4A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.